Carmofur是一种强效的大鼠重组酸性神经酰胺酶抑制剂，IC50值为29nM。
Cas No.:61422-45-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Carmofur is a potent inhibitor of rat recombinant acid ceramidase with an IC50 value of 29nM [1]. Carmofur binds to the main protease (Mpro) of SARS-CoV-2, where the carbonyl group is covalently bound to catalytic Cys145 thus inhibiting the activity of Mpro[2]. Carmofur has been widely used to inhibit tumor progression and to block multidrug-resistant Streptococcus pneumoniae infection[3].
In vitro, Carmofur treatment for 24 hours significantly inhibited the proliferation of SJGBM2, CHLA200, and CHLA266 cells with IC50 values of 50µM, 13µM and 15µM, respectively[4]. Carmofur treatment for 12h significantly induced cell death in irradiated U87-10gy cells, accompanied by an increase in ceramide levels[5]. Treatment of U251T cells with 20µM Carmofur for 48 hours significantly promoted cell cycle alterations, induced apoptosis and decreased E2F8 mRNA expression in U251T cells [6].
In vivo, Carmofur treatment via oral administration at a dose of 10mg/kg (twice a day) for 3 days ameliorated the inflammatory responses and promoted the resolution of pulmonary injury in lipopolysaccharide (LPS)-treated mice[7]. Daily intraperitoneal injection of 750µg (dissolved in 100µl corn oil) of Carmofur for 10 days attenuated parasitemia and decreased reticulocyte frequency in mice during Plasmodium yoelii infection [8].
References:
[1] Realini N, Solorzano C, Pagliuca C, et al. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity[J]. Scientific reports, 2013, 3(1): 1035.
[2] Islam M M, Mirza S P. Versatile use of Carmofur: A comprehensive review of its chemistry and pharmacology[J]. Drug Development Research, 2022, 83(7): 1505-1518.
[3] Lyu W, Zhang Y, Zhang Z, et al. Carmofur Exhibits Antimicrobial Activity Against Streptococcus pneumoniae[J]. Antibiotics, 2025, 14(3): 231.
[4] Doan N B, Nguyen H S, Montoure A, et al. Acid ceramidase is a novel drug target for pediatric brain tumors[J]. Oncotarget, 2017, 8(15): 24753.
[5] Doan N B, Nguyen H S, Al-Gizawiy M M, et al. Acid ceramidase confers radioresistance to glioblastoma cells[J]. Oncology Reports, 2017, 38(4): 1932-1940.
[6] Hawkins C C, Jones A B, Gordon E R, et al. Carmofur prevents cell cycle progression by reducing E2F8 transcription in temozolomide-resistant glioblastoma cells[J]. Cell death discovery, 2023, 9(1): 451.
[7] Wu K, Xiu Y, Zhou P, et al. A new use for an old drug: carmofur attenuates lipopolysaccharide (LPS)-induced acute lung injury via inhibition of FAAH and NAAA activities[J]. Frontiers in pharmacology, 2019, 10: 818.
[8] Günther A, Hose M, Abberger H, et al. The acid ceramidase/ceramide axis controls parasitemia in Plasmodium yoelii-infected mice by regulating erythropoiesis[J]. Elife, 2022, 11: e77975.
Carmofur是一种强效的大鼠重组酸性神经酰胺酶抑制剂，IC50值为29nM[1]。Carmofur与SARS-CoV-2的主要蛋白酶（Mpro）结合，Carmofur的羰基与酶催化位点的Cys145共价结合，从而抑制Mpro的活性[2]。Carmofur已被广泛用于抑制肿瘤进展以及阻断多重耐药肺炎链球菌感染[3]。
在体外，Carmofur处理24小时显著抑制了SJGBM2、CHLA200和CHLA266细胞的增殖，IC50值分别为50µM、13µM和15µM[4]。Carmofur处理12小时显著诱导了辐照后U87-10gy细胞的死亡，伴随神经酰胺水平的升高[5]。使用20µM的Carmofur处理U251T细胞48小时，显著促进了细胞周期改变，诱导了细胞凋亡，并降低了细胞中E2F8 mRNA的表达[6]。
在体内，每日口服两次10mg/kg剂量的Carmofur，连续3天，减轻了脂多糖（LPS）处理小鼠的炎症反应并促进了肺损伤的消退[7]。每日腹腔注射750µg的Carmofur（溶于100µl玉米油），连续10天，减轻了Plasmodium yoelii感染小鼠的寄生虫血症并降低了网织红细胞频率[8]。
| Cell experiment [1]: | |
Cell lines | CHLA259 cells |
Preparation Method | CHLA259 cells were cultured in Iscove's modified Dulbecco's medium containing 20% fetal bovine serum (FBS), 4mM L-glutamine, 5μg/ml insulin, 5μg/ml transferrin, and 5ng/ml selenous acid at 37℃ in the presence of 5% CO2. Cells were plated onto a 96-well plate at a density of 1×105 cells/ml for 24h, and were treated with different concentrations of Carmofur (1, 10, 20, 40, 60, 80, and 100µM). After 24 hours, cell viability was analyzed. |
Reaction Conditions | 1, 10, 20, 40, 60, 80, and 100µM; 24h |
Applications | Carmofur treatment significantly decreased the cell viability of CHLA259 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6J mice |
Preparation Method | Male C57BL/6J mice (20-22g) were randomly grouped, with eight mice for each group. Mice were anesthetized with chloral hydrate and instilled intratracheally with LPS (5mg/kg). Carmofur (10mg/kg; dissolved in saline with 5% polyethylene glycol 400 and 5% Tween 80) or vehicle was orally administered twice a day starting from the day of LPS application. Mice were sacrificed 3 days after LPS instillation. Mouse lung tissues were collected for analysis. |
Dosage form | 10mg/kg; twice a day for 3 days; p.o. |
Applications | Carmofur treatment ameliorated the inflammatory responses and promoted the resolution of pulmonary injury in mice. |
References: | |
| Cas No. | 61422-45-5 | SDF | |
| 别名 | 卡莫氟; HCFU | ||
| 化学名 | 5-fluoro-N-hexyl-2,4-dioxopyrimidine-1-carboxamide | ||
| Canonical SMILES | CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F | ||
| 分子式 | C11H16FN3O3 | 分子量 | 257.26 |
| 溶解度 | ≥ 12.2mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8871 mL | 19.4356 mL | 38.8712 mL |
| 5 mM | 777.4 μL | 3.8871 mL | 7.7742 mL |
| 10 mM | 388.7 μL | 1.9436 mL | 3.8871 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet